Pyoderma gangrenosum is a diagnosis of exclusion, and the misdiagnosis of pyoderma gangrenosum can result in substantial complications in patients who have other causes of severe cutaneous ulceration.

The study pointed to TNF blockade as a potential therapeutic option for patients with OTULIN-related pyoderma gangrenosum. The investigators noted that one patient, whose painful skin sores were ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

Leg ulcers form when skin on your leg breaks open. These breaks or sores let air and bacteria travel into your skin’s tissue. For most people, leg ulcers will heal on their own and won’t need medical ...

Pyoderma gangrenosum (PG) is a rare, ulcerative skin condition of unknown origin, with an annual incidence of 3 to 10 cases per million people. Skin lesions develop as painful, edematous nodules or ...

A 59-year-old woman with systemic lupus erythematosus presented with a 1-month history of an enlarging, exquisitely painful ulcer on her left calf (Figure 1). She reported that it had occurred ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Ulcerative pyoderma gangrenosum is a rare disease with ...

An 80-year-old woman with advanced renal cell carcinoma with multiple pulmonary metastases presented to the Department of Dermatology after a 2-month history of a slowly enlarging, painful ulcer that ...

Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...